Dear All: CARB-X have just announced their 2nd 2026 call for applications. There are 4 thematic areas for your proposals: Direct-acting therapeutics for infections caused by Gram-negative bacteria “Proposals must target the development of agents for the treatment of Gram-negative priority pathogens” (see our Bugs & Drugs page). Novel Chemistry for AMR Challenge: target-based therapeutics
Dear All: Starting to get caught up after some time on vacation! For today, we have announcement by CARB-X of the posting of two openings for the role of Assistant Directors of External Affairs. Here are the links: Official webpage: https://jobs.silkroad.com/BU/External/jobs/316699 LinkedIn post: https://www.linkedin.com/posts/damianodefelice_job-opportunity-vacancy-share-7461081369562066944-tS7O A few excerpts from the job description: “The Assistant Director of
Dear All, Novel antibacterial agents, vaccines, and diagnostics will do little if they are not widely available and used responsibly. CDDEP’s recent report entitled “The State of the World’s Antibiotics in 2021” makes this very clear: “… more people in LMICs (low-middle-income countries) die from lack of access to antimicrobials than from resistant infection.” Hence, CARB-X has
Dear All, At BEAM’s AMR Conference in Basel, Team CARB-X have today announced their 2025 funding round. Key points: Two themes: (i) Direct-acting small molecule therapeutics for Gram-negatives (same as in 2024) and (ii) diagnostics for typhoid fever in low-resource settings. 23 Mar 2025 newsletter update: The TPPs for both themes have been released: Small
Dear All, Four big reports have recently been released and are very much worth reviewing. First, the Global AMR R&D Hub and the WHO AMR Team have written a report entitled “Incentivising the development of new antibacterial treatments“. This report is a response to a 2021 request by the G7 Finance Ministers for a report on
Dear All (and with thanks to Damiano for co-authoring), We have exciting news from the G7 Health Ministers’ Meeting, which was held in person in Ancona on 9-11 October 2024, and the accompanying G7 Joint Finance and Health Ministers’ Meeting, which took place in a hybrid format on 10 October 2024. At the press conference closing
Dear All, CARB-X have opened their 2nd funding round for 2024! The Expression of Interest (EoI) deadline is 4 Oct 2024, so time is short! The 2nd round has the same 4 basic areas as the first round (see 6 Mar 2024 newsletter for reference): Therapeutics for Infections Caused by Gram-Negative Pathogens (WHO and CDC
Dear All: There has been tremendously exciting activity in parallel with this week’s World Health Assembly! Here’s the list… CARB-X has announced this week that the Bill & Melinda Gates Foundation and the UK government will contribute $25 million and £20 million ($26.9 million), respectively, over the next 3 years. With this new inflow of $50m in committed funds,
Dear All, Heads up! Having just yesterday announced funding of its 100th project, CARB-X have today announced two funding rounds for 2024. With application dates of 18-29 Mar 2024 and 23 Sep-4 Oct 2024, applications are sought on 4 major areas (see extended details below my signature): Therapeutics for Infections Caused by Gram-Negative Pathogens (WHO and
Dear All (and with thanks to Damiano, Peter and Aleks for co-authoring), Some great news to start off 2024 on the right foot: the Novo Nordisk Foundation has announced that it will fund CARB-X with a three-year grant of USD 25 million! The Novo Nordisk Foundation joins four governments (Canada, Germany, the United Kingdom, and the United States)